Technology Listings

Reprogramming of Fibroblasts toward a Three-Dimensional Vascularized Cardiomimetic Tissue (CMT)


Fibroblasts reprogrammed into tissue-like patch including functional cardiomyocyte, endothelial, smooth muscle and pericyte cells for treatment of cardiac diseases.

Key Benefits
  • Enables simultaneous reprogramming of multi-lineage cells including cardiomyocytes and endothelial cells
  • Increases expression of cardioprotective paracrine factors.
  • Provides cardiac functionality, with demonstrated muscle contractility.
Market Summary

Ischemic heart disease or coronary artery disease is the single leading cause of death and disability worldwide with over 600,000 deaths and 715,000 new heart attacks a year. Mycoardial function is sensitive to ischemia, which can result in damage to tissue. Cell therapy is a treatment option for myocardial regeneration, however low efficiency for generating cardiomyocytes, low retention following cell transplantation, immunologic incompatibility, and tumor formation limit its clinical application. Stem cell technologies offer promise for myocardial regeneration, but the inability to generate functional cardiomyocytes versus non function smooth muscle cells remains the largest limitation.

Technical Summary

Researchers at Emory University have developed a heart patch capable of reprograming fibroblasts into cardiac tissue cells. This patch may be placed on the heart to help regenerate tissue and heal the heart following ischemia. A combination of miRNA, ascorbic acid, and bone morphogenic protein 4 (BMP4) simultaneously reprogrammed mouse dermal fibroblasts into cardiomimetic tissues (CMT) including functional cardiomyocyte, endothelial, smooth muscle, and pericyte cells. The CMT may be used as a platform in cell therapy for cardiac diseases, investigations of disease processes and modeling, or testing various drugs.

Developmental Stage

In vivo study in mouse model completed.

Publication: Cho, J. et al. Circulation. 2014; 130:A15412

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Utility(parent) United States 14/933,052 10,206,955 11/5/2015 2/19/2019 9/10/2036 Issued
Divisional United States 16/275,602 2/14/2019     Pending
Tech ID: 14150
Published: 7/19/2016

John Nicosia
Licensing Associate
Emory University

Young-Sup Yoon
Jaeyeaon Cho

Cell/Gene Therapy
Regenerative Medicine